Pharmaceutical Sales Jobs | Pharmaceutical sales | Pharma jobs

The Federal Trade Commission is tightening the rules for who is a paid endorser and what advertisers
need to disclose about them. Look for new transparency on payment and new language to replace "your mileage
may vary."

The already crowded health portal market will get a bit tighter with the addition of
myOptumHealth.com. But unlike the other WebMDs of the world (wide Web), Optum comes with a built-in base of 60
million users and the muscle of the UnitedHealth Group.

Big name patent expirations may be looming, but that’s not stopping pharma companies from filing – and
getting approved for – dozens of new patents. Pharm Exec looks at which companies are getting the most approvals,
and how 2008 compared to previous years.

Pfizer hit hard with the surprise purchase of Wyeth. But will the pharma giant strike out in the long
run? Analysts ponder the long and short-term ramifications of this monster acquisition.

Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough
to get the biotech’s board of directors to sign on the dotted line.

The pharma industry has come a long way since Hurricane Katrina when it comes to disaster planning.
Now, with experts predicting an influenza pandemic, companies have a chance to prepare systems before a crisis
happens.

Pfizer hit hard with the surprise purchase of Wyeth. But will the pharma giant strike out in the long
run? Analysts ponder the long and short-term ramifications of this monster acquisition.

Big name patent expirations may be looming, but that’s not stopping pharma companies from filing – and
getting approved for – dozens of new patents. Pharm Exec looks at which companies are getting the most approvals,
and how 2008 compared to previous years.

Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough
to get the biotech’s board of directors to sign on the dotted line.

As pharmaceutical companies look to emerging markets to offset slowed growth at home, success will
depend on efficient re-use of regulatory content to target new high-growth markets.